EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Bulevirtide in Chronic Hepatitis D Patients Awaiting Liver Transplantation Results From a French Multicentric Retrospective Study

Magdalena Meszaros iD, Marie-Noëlle Hilleret, Jérôme Dumortier iD, Louis D'Alteroche, Armand Abergel, Marianne Latournerie, Teresa Antonini, Filomena Conti, Patrick Borentain, Sébastien Dharancy, Georges-Philippe Pageaux iD

Liver International · 2025-03 · 45 (3)

DOI: 10.1111/liv.70033 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Liver International, online erschienen am 17.02.2025. Verfasst von Magdalena Meszaros und 10 weiteren Autor:innen. Beteiligte Einrichtung: Liver Transplantation and Hepatogastroenterology Unit, CHU Montpellier, CHU Montpellier, Montpellier, France. Hauptthemen laut MEDLINE: Liver Transplantation, Hepatitis D, Chronic, Antiviral Agents, Peptide Fragments. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims The impact of bulevirtide in patients awaiting liver transplantation (LT) for decompensated liver disease and/or hepatocellular carcinoma (HCC) is unclear. We assessed clinical, virological, and biochemical responses to bulevirtide in patients with chronic hepatitis delta virus (HDV) awaiting LT and compared outcomes with a cohort of similar untreated patients.

Methods

Consecutive HDV‐infected patients waiting for LT since bulevirtide approval were included. Patients receiving 2 mg of bulevirtide daily had clinical, biological, and virological data collected at baseline, Week 24, Week 48, at LT, and post‐LT. Patients not receiving bulevirtide had data collected at baseline, LT, and post‐LT for comparison.

Results

Forty‐one patients from nine LT centers were included. In the bulevirtide group (20 patients; mean age 52.8 ± 9.98 years; 75% male), 65%, 10% and 25% were Child‐Pugh A, B and C, respectively. Fifteen completed 48 weeks of therapy. At 48 weeks, median HDV RNA decreased by 2.56 log IU/mL ( p = 0.004). Virological and biochemical responses were obtained in 73.3% and 66.6% of patients. Twelve patients (60%) underwent LT. No serious adverse events occurred. Bulevirtide improved liver function, enabling one (7.1%) HCC patient to undergo chemoembolization while on the WL and leading to delisting of three (15%) other patients. In untreated patients (mean age 42.9 ± 7.9 years; 76.2% Child‐Pugh C), none were delisted. Three‐month transplant‐free survival was 76.9% in the bulevirtide group versus 36.7% ( p = 0.007) in the control group.

Conclusions

Bulevirtide demonstrates safety and efficacy in HDV‐infected patients listed on the LT waiting list and may potentially improve pre‐transplant outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver TransplantationHepatitis D, ChronicAntiviral AgentsPeptide FragmentsHumansMaleFemaleMiddle AgedFranceRetrospective StudiesAdultCarcinoma, HepatocellularHepatitis Delta VirusLiver NeoplasmsWaiting ListsRNA, ViralViral LoadTreatment Outcome

Stichwörter der Autor:innen

bulevirtidechronic hepatitis Dliver transplantationsafetyvirological response

Substanzen

Antiviral AgentsRNA, ViralPeptide Fragments

Autor:innen und Institutionen

  • Liver Transplantation and Hepatogastroenterology Unit, CHU Montpellier, CHU Montpellier, Montpellier, France.
  • Hepato-Gastroenterology Unit, CHU Grenoble Alpes, Grenoble, France.
  • Digestive Diseases Federation, Edouard Herriot Hospital, Hospices Civils de Lyon, Université Claude Bernard Lyon 1, Lyon, France.
  • Hepatogastroenterology Unit, CHU Tours, Tours, France.
  • Hepatogastroenterology Unit, CHU Estaing Clermont-Ferrand, Clermont-Ferrand, France.
  • Hepatogastroenterology Unit, CHU Dijon, Dijon, France.

ORCID-Profile: Magdalena Meszaros, Jérôme Dumortier, Georges-Philippe Pageaux

Zitieren

APA

Meszaros, M., Hilleret, M. N., Dumortier, J., D'Alteroche, L., Abergel, A., Latournerie, M., Antonini, T., Conti, F., Borentain, P., Dharancy, S., & Pageaux, G. P. (2025). Bulevirtide in Chronic Hepatitis D Patients Awaiting Liver Transplantation Results From a French Multicentric Retrospective Study. Liver International, 45(3). https://doi.org/10.1111/liv.70033

Vancouver

Meszaros M, Hilleret MN, Dumortier J, D'Alteroche L, Abergel A, Latournerie M, et al. Bulevirtide in Chronic Hepatitis D Patients Awaiting Liver Transplantation Results From a French Multicentric Retrospective Study. Liver International. 2025;45(3). doi:10.1111/liv.70033

BibTeX
@article{Meszaros2025,
  author = {Meszaros, Magdalena and Hilleret, Marie-Noëlle and Dumortier, Jérôme and D'Alteroche, Louis and Abergel, Armand and Latournerie, Marianne and Antonini, Teresa and Conti, Filomena and Borentain, Patrick and Dharancy, Sébastien and Pageaux, Georges-Philippe},
  title = {Bulevirtide in Chronic Hepatitis D Patients Awaiting Liver Transplantation Results From a French Multicentric Retrospective Study},
  journal = {Liver International},
  year = {2025},
  volume = {45},
  number = {3},
  doi = {10.1111/liv.70033}
}
Kostenlos starten →